The COG SDC consists of experienced Ph.D. level statisticians located at major universities directing the statistical analysis of COG data. In addition to this strong core of professionals, COG data are collected, managed and archived at one location: the COG Research Data Center at the University of Florida in Gainesville FL. This model combines the experience of professional statisticians, some of who have worked in pediatric oncology for more than 20 years, with a data management center with a long history of service to the pediatric research community. This model provides significant advantages to the research agenda of COG. The statistical leadership is comprised of individuals with significant experience in the design and analysis of clinical trials. Data are collected at a single site using uniform conventions and overseen by individuals with years of experience in this area. This makes data collection more efficient for institutional investigators and promotes the aggregation of large databases representing years of clinical trials work. The major goals of the SDC are: (1) participate in setting Group scientific priorities in specific disease areas through membership on strategy groups, tasks forces, and discipline committees; (2) evaluate COG therapeutic, epidemiologic, and biologic studies that are proposed or in development, to ensure the stated study aims can be accomplished (3) provide a study design, data acquisition plan and study analysis plan that ensures the study aims will be addressed correctly and efficiently, with appropriate monitoring of patient safety. (4) Perform statistical analyses of data relevant to interim monitoring and final reporting of the results of COG studies; (5) ensure that the needs of COG studies for data collection, computerization, report generation, committee review, safety monitoring, data quality control and institutional performance are met; (6) Investigate and test current information technology tools and adopt those that provide the most efficient means of quality data collection; (7) Establish policies for study conduct that ensure appropriate evaluation of study questions; (8) develop or extend statistical methodology to address unique problems arising in Group investigations; and (9) Provide training in the statistical aspects of the Group's scientific endeavors to various members of COG.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA098413-01
Application #
6561230
Study Section
Subcommittee G - Education (NCI)
Program Officer
Smith, Malcolm M
Project Start
2003-06-20
Project End
2005-02-28
Budget Start
2003-06-20
Budget End
2004-02-29
Support Year
1
Fiscal Year
2003
Total Cost
$6,215,919
Indirect Cost
Name
National Childhood Cancer Foundation
Department
Type
DUNS #
624124301
City
Arcadia
State
CA
Country
United States
Zip Code
91006
Alexander, Thomas B; Gu, Zhaohui; Iacobucci, Ilaria et al. (2018) The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature 562:373-379
Dix, David B; Seibel, Nita L; Chi, Yueh-Yun et al. (2018) Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study. J Clin Oncol 36:1564-1570
Fernandez, Conrad V; Mullen, Elizabeth A; Chi, Yueh-Yun et al. (2018) Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532. J Clin Oncol 36:254-261
Rau, Rachel E; Dreyer, ZoAnn; Choi, Mi Rim et al. (2018) Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. Pediatr Blood Cancer 65:
Burke, Michael J; Devidas, Meenakshi; Maloney, Kelly et al. (2018) Severe pegaspargase hypersensitivity reaction rates (grade ?3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials. Leuk Lymphoma 59:1624-1633
Urtishak, Karen A; Wang, Li-San; Culjkovic-Kraljacic, Biljana et al. (2018) Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia. Oncogene :
Ariƫs, Ingrid M; Bodaar, Kimberly; Karim, Salmaan A et al. (2018) PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. J Exp Med 215:3094-3114
Gupta, Sumit; Devidas, Meenakshi; Loh, Mignon L et al. (2018) Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG). Leukemia 32:1370-1379
Malempati, Suman; Weigel, Brenda J; Chi, Yueh-Yun et al. (2018) The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer :
Mansour, Marc R; He, Shuning; Li, Zhaodong et al. (2018) JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia. J Exp Med 215:1929-1945

Showing the most recent 10 out of 473 publications